SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Sandoz logo
3 months ago

Director of Market Access Strategy & Planning (2 positions)

Sandoz

Princeton, NJ (Hybrid)Full time$195K/yr – $361K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Sandoz logo

Director of Market Access Strategy & Planning (2 positions)

Sandoz

Princeton, NJ (Hybrid)

$195K/yr - $361K/yrIn-houseFull-timeDirector/executive10+ years exp.
3 months ago
Sandoz logo
Sandoz

Director of Market Access Strategy & Planning (2 positions)

Princeton, NJ (Hybrid)

$195K/yr – $361K/yrDirector/Executive10+ years expFull time

Posted 3 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive market access strategy and policy impact for launches and lifecycle management in Sandoz portfolio.

  • Own cross-functional value and access initiatives across launches and in-line products.
  • Must-have: 10+ years in pharmaceutical market access and cross-functional project leadership.
  • Standout: Translate policy changes into pricing and reimbursement actions with multi-stakeholder teams.

Job Description

Responsibilities

  • Core member of Launch Management Teams and/or Brand Teams.
  • New Product Launches: Responsible for leading cross-functional collaboration in the design of near-term launches and working with global colleagues for mid-long term launches.
  • In-Line Products: Responsible for continuing Life Cycle Management monitoring and strategy adjustment activities for products throughout the life cycle.
  • Evaluate and analyze the impact of current and future policy (e.g. Inflation Reduction Act, annual CMS changes, etc.) to the Sandoz portfolio as well as shape the strategic direction of future policy initiatives with Government Affairs and Government Pricing
  • Advise on market access, pricing, and reimbursement strategy by incorporating key government considerations for both in-line and launch product
  • Educate and train cross-functional team members and prepare solutions for market access evolution and best practices (e.g. Medicare Advantage, Med D design changes, payer evolution, medical management, 340B stacking, etc.)
  • Assess impact of market access considerations (pricing [gross & net], adoption, payer acceptance, provider acceptance, etc.) on forecasts and NPV
  • Able to successfully pivot with rapidly evolving market dynamics, between products, and between stakeholders without losing sight of strategic pillars.
  • Work with numbers/excel, including working with Finance on forecasts, Analytics on data & insights, and Account Strategy on account business cases.

Requirements

  • BA / BS required, MBA preferred.
  • Minimum 10 years of experience in project management experience, 7 years in pharmaceuticals required.
  • Business case management.
  • Deep understanding of Brand Management and evolution across regions.
  • Experience working cross-functionally and trans-nationally.
  • Strong familiarity with government pricing principles: IRA, AMP, ASP, Best Price, NonFamp, 340B, etc.
  • Strong capability assessing government policy impact to existing and future portfolio
  • Responsible for market access consideration for any new product pipeline product
  • Strat planning for market access to identify trends and solutions important to the business
  • Thorough understanding of market access considerations for future pipeline, including TPP, labeling, packaging, etc.
  • Travel may be as high as 20%, with a requirement for regular field visits with account managers in target accounts and attendance at appropriate meetings/congresses.

Preferred

  • MBA preferred.

Benefits

  • Sandoz offers a generous employee benefits package that includes a competitive salary, health insurance coverage for medical, prescription drugs, dental and vision, a generous company match for retirement savings accounts, and generous paid time off.
  • We follow a hybrid work policy that combines a mix of in-person and remote work to allow our employees flexibility.
Sandoz logo

Sandoz

3.9 Glassdoor

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars.Read our community engagement guidelines: http://bit.ly/4ofoggc

Basel, Basel, CHE
17K employees (844 in marketing)
www.sandoz.com
78% recommend to a friend
84% CEO approval

Traffic Signals

Monthly Visitors
195.2K
Monthly Google Ads Budget
$5.3K
Traffic Source Mix
Search
52.9%
Direct
31.9%
Referral
8.8%
Social
5%
Paid
1.1%

Headcount Trend

Current headcount: ~17.3K

Marketing Team

Marketing Team Size
752 (4% of company)

Funding

Total Funding
$3.6B
Last Raise
$667.3M
Post IPO Debt, 1 years ago

Funding History

  • Sep 2024
    Post IPO Debt • $667.3M
  • Nov 2023
    Post IPO Debt • $2.9B

Recent News

Rheumatoid Arthritis Therapeutics Market Trends Analysis Report 2025-2033 by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter)
Sep 26, 2025 • Research and Markets
Encephalopathy Market Worth $209 Million in 2025 Led by Salix Pharma, Abbott Labs, and Fresenius Kabi: Analysis of Key Trends & Strategies
Sep 11, 2025 • Research and Markets
Triamterene Capsules Market set to hit $1437.5 million by 2035
Aug 12, 2025 • PRLog
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
Aug 12, 2025 • Morningstar.com
Vistogard Market set to hit $3.2 billion by 2035
Aug 12, 2025 • PRLog
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Aug 7, 2025 • Sandoz International GmbH
Tinnitus Market Analysis and Forecast Report 2025-2035 | Pharma Giants Drive Treatment Advances with Off-Label CNS Drugs Amid Intensifying Market Competition
Jul 24, 2025 • Research and Markets
Hydrocortisone Market Report 2025 – Strategic Insights For Companies Seeking Expansion, Growth & Competitive Advantage
Jul 2, 2025 • EIN Presswire
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
Jul 1, 2025 • Sandoz International GmbH
Biosimilars Market worth US$72.29 billion by 2035 with 7.5% CAGR | MarketsandMarkets™
Jun 17, 2025 • PR Newswire UK
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Jun 2, 2025 • Sandoz International GmbH
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Jun 2, 2025 • GlobeNewswire
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Jun 1, 2025 • Morningstar.com
Alcohol Use Disorder (AUD) Market Trends and Forecasts (2025-2030) by Drug Class, Treatment Type, End User, Distribution Channel, Formulation, Region and Country
May 29, 2025 • Research and Markets
Cyclosporine Global Market Report 2025: Sweeping Across the Globe with Heightened Demand and Market Growth
May 28, 2025 • EIN Presswire
Primary Driver In The Galantamine Hydrobromide Market 2025: Rising Prevalence Of Alzheimer’s Disease Driving Market
May 27, 2025 • EIN Presswire
Business news in Slovenia
May 13, 2025 • sloveniabusiness.eu
Sandoz Egypt introduces OMNITROPE 15mg biosimilar growth hormone for the treatment of short stature
May 11, 2025 • Zawya.com
Tysabri (natalizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034
May 8, 2025 • Research and Markets
Sandoz reports first-qtr 2025 net sales growth of 3%
Apr 30, 2025 • Pharma Letter
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Apr 29, 2025 • Morningstar.com
Active Pharmaceutical Ingredients (API) Market to Amass $359.45 Billion by 2030 at CAGR 5.85% - Grand View Research, Inc.
Apr 29, 2025 • PR Newswire
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
Apr 29, 2025 • BioSpace
Forecasting The Biosimilars Market: A CAGR Of 17.60% By 2035
Apr 16, 2025 • PharmiWeb
Key Driver Transforming The Adrenogenital Syndrome Treatment Market 2025: Increasing Adoption Of Personalized Medicines
Mar 24, 2025 • EIN Presswire
Donald Trump’s $1.4 trillion tariff threats scramble business plans, US companies form task-forces to tackle impact
Mar 13, 2025 • mint
Naloxone Market to Surge to US$ 3.6 Billion by 2033, Expanding at 10.3% CAGR
Feb 28, 2025 • EIN Presswire
Biosimilars Market Role in Reducing Healthcare Costs and Expanding Patient Accessibility - Forecasted to grow to USD 85 billion by 2031
Dec 9, 2024 • PharmiWeb.com
Blow-Fill-Seal Technology Market Growth Analysis with Investment OpportunitiesFor 2024-2033
Oct 31, 2024 • EIN Presswire
Blow-Fill-Seal Technology Market Growth Analysis with Investment Opportunities For 2024-2033
Oct 30, 2024 • EIN Presswire
Sandoz on LinkedIn: Sandoz, the global leader in generic and biosimilar medicines, today…
Mar 13, 2024 • LinkedIn
Sandoz To Pay $195M For Generic-Drug Antitrust Violations
Mar 2, 2020 • Law360
Francesco Balestrieri appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis
Mar 15, 2019 • EuropaWire.eu
Sandoz certified “TOP Employer Asia Pacific 2019” for its exceptional employee offerings in the region
Dec 4, 2018 • EuropaWire.eu
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
May 2, 2018 • acnnewswire.com
LSD: Wunderdroge oder Wahnsinnsdroge?
Apr 19, 2018 • DW
Sandoz HACk – Healthcare Access Challenge seeks young people with innovative ideas to “reimagine” access to healthcare
Oct 5, 2016